China Medical System’s CMS-D003 Receives NMPA Approval for Clinical Study in oHCM
China Medical System Holdings (CMS; HKG: 0867) announced receiving approval from the National Medical Products...
HKG: 0867
China Medical System Partners with MabGeek for Innovative Drug MG-K10
China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...
China Medical System Licenses Alpha Cognition’s Zunveyl for Dementia Treatment in Asia
China Medical System Holdings (CMS; HKG: 0867) has announced a license agreement with Alpha Cognition...
China Medical System’s Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use
China Medical System Holdings (CMS; HKG: 0867) has announced that the first prescriptions have been...
China Medical System Holdings Secures Exclusive Rights to Atom Therapeutics’ Gout Drug ABP-671
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with compatriot...
China Medical System Holdings Gets NMPA Approval to Test Obesity Treatment CMS-D005
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval...
China Medical System’s Opzelura Approved in Hong Kong for Non-segmental Vitiligo Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced that the market filing for its...
China Medical System’s Opzelura Cream Filing for Vitiligo Accepted by NMPA
China Medical System Holdings (CMS; HKG: 0867) has announced that its market filing for Opzelura...
CMS’s Methotrexate Injection Gains NMPA Approval for Active Rheumatoid Arthritis Treatment
China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...
China Medical System’s Methylthioninium Tablets Get NMPA Green Light for Colonoscopy Use
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received New Drug...
China Medical System Secures Exclusive Rights to Baiyiyuan Biotech’s Implant in Greater China
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with Shanghai-based...
China Medical System Holdings’ Desidustat NDA Accepted for Review by China’s NMPA
China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...
China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...
China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases
China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement...
China Medical System Gets Green Light for Phase III Clinical Trial of Opzelura in Atopic Dermatitis
China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...
CMS Secures NMPA Approval for Clinical Trials of TYK2 Inhibitor CMS-D001 and GnRH Antagonist CMS-D002
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received clinical...
China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a rights assignment agreement with...
China Medical System Holdings Secures Exclusive Rights to Promote Xihong Biopharma’s Aesthetic Fillers
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi...
China Medical System Expands into Southeast Asia with Singapore Manufacturing Plant Lease
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend...
China Medical System Gets NMPA Green Light for Phase III Vitiligo Study with Ruxolitinib Cream
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...